Only those family members with a co-occurrence of a mutation in BMPR2 and EIF2AK4 were clinically affected and developed manifest HPAH, whereas carriers of the BMPR2 mutation only had no symptoms of PAH. Here, EIF2AK4 is linked to pulmonary arterial hypertension.